Hokuriku Pharmaceutical announced that the company's deputy general manager Zong Li's holdings reduction plan has been completed. From July 14, 2026 to August 28, 2026, Zong Li reduced its holdings of the company's shares by a total of 30,600 shares through centralized bidding, accounting for 0.0053% of the company's total share capital, with an average reduction price of 9.05 yuan/share. Before the current reduction, Zongli held a total of 122,400 shares of the company, accounting for 0.0210% of the total share capital; after the reduction, it held 91,800 shares, accounting for 0.0158% of the total share capital. This reduction in holdings will not lead to a change in the company's control and will not affect corporate governance and ongoing operations.

Hokuriku Pharmaceutical announced that the company's deputy general manager Zong Li's holdings reduction plan has been completed. From July 14, 2026 to August 28, 2026, Zong Li reduced its holdings of the company's shares by a total of 30,600 shares through centralized bidding, accounting for 0.0053% of the company's total share capital, with an average reduction price of 9.05 yuan/share. Before the current reduction, Zongli held a total of 122,400 shares of the company, accounting for 0.0210% of the total share capital; after the reduction, it held 91,800 shares, accounting for 0.0158% of the total share capital. This reduction in holdings will not lead to a change in the company's control and will not affect corporate governance and ongoing operations.